What patent covers lenvatinib “dppa cyclopropylamine”?
I don’t have enough information in the provided context to identify a specific patent that mentions “lenvatinib dppa cyclopropylamine.” Patent records usually require at least one of the following to match correctly: the exact chemical name spelling as filed, a patent number/publication number, the assignee/company, or a jurisdiction (US/EPO/WO).
If you share any one of these, I can pinpoint the correct patent record and summarize the claims:
- the patent/publication number (e.g., WO…, US…),
- the applicant/assignee (company or institute),
- the country (US/EPO/WO),
- a link or screenshot of the patent text where “dppa cyclopropylamine” appears.
Is “dppa cyclopropylamine” part of lenvatinib, a salt, or an intermediate?
Search results depend heavily on whether “dppa cyclopropylamine” is:
- a component of the final drug substance (lenvatinib itself or a specific salt/formulation),
- a key intermediate used to make lenvatinib,
- or a reagent/chemical naming fragment that appears in a synthesis example.
Patents sometimes include reagents and intermediates in the examples, even when the independent claims are directed to the final compound or a specific salt/crystalline form. Knowing whether the phrase appears in examples vs. claims determines how directly it links to the protected subject matter.
How can I find the exact patent quickly (what to search for)?
To locate the patent that contains the phrase, use targeted keyword searches in patent databases (Google Patents, Espacenet, or The Lens) for combinations such as:
- “lenvatinib” AND “cyclopropylamine”
- “lenvatinib” AND “dppa”
- “dppa” AND “cyclopropylamine” (then filter results for lenvatinib)
- restrict by assignee if you know the maker (commonly Eisai for lenvatinib, but you’d need confirmation from your source)
If you tell me which database you’re using and what you see around the phrase (claims vs. examples), I can suggest the most effective filters and interpret the relevance.
When does lenvatinib patent protection typically expire (and how that affects this)?
Even after an active compound patent expires, drug exclusivity can persist via:
- patents on specific formulations (salt/crystal forms),
- manufacturing processes,
- or additional therapeutic-use patents.
Your specific phrase (“dppa cyclopropylamine”) may relate to one of these secondary protections (often process/intermediate-related) rather than the core active ingredient patent. Exact timelines depend on the specific patent family and jurisdiction, so the patent number/family is required to calculate or verify expiry.
What do you want to learn from the patent?
Different users search for different outcomes, for example:
- whether the patent blocks generic entry (ANDA/Biologics not relevant here, but small-molecule generics are),
- what the claims actually cover (composition vs. method vs. process),
- whether the phrase appears in a synthesis example only,
- and who owns it (assignee).
Reply with the patent number or paste the snippet that includes “dppa cyclopropylamine,” and I’ll identify the patent and summarize what it claims and how it connects to lenvatinib.